Clinical trial NCT02905682: Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects
Official title: A Randomised, Double-blind, Placebo-controlled, Multi-centre Trial Investigating the Efficacy and Safety of Desmopressin (FE 992026) Orally Disintegrating Tablets During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Nocturia
Lead sponsor: Ferring Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2016-09-19
Enrollment: 190
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this trial is to demonstrate efficacy of desmopressin ODT against placebo for the treatment of female subjects with nocturia due to nocturnal polyuria, during 12 weeks of treatment.


Eligibility criteria: Inclusion Criteria:

* Written informed consent prior to performance of any trial-related activity
* Woman ≥20 years of age
* Nocturia symptoms present for ≥6 months prior to trial entry at Visit 1
* ≥2 nocturnal voids at the end of screening period prior to Visit 2
* Nocturnal polyuria at the end of screening period prior to Visit 2
* Bothered by nocturia on the Hsu 5-point Likert bother scale at Visit 1 and Visit 2
* Has given agreement about contraception during the trial

Exclusion Criteria:

* Evidence of any significant voiding dysfunction resulting in abnormally low bladder capacity at the end of the screening period prior to Visit 2
* History or evidence of significant obstructive sleep apnoea
* History or diagnosis of any of the following urological diseases at Visit 1:

  * Interstitial cystitis or bladder pain disorder
  * Stress urinary incontinence or mixed incontinence, where stress incontinence is the predominant component based on prior history
  * Chronic pelvic pain syndrome
* Surgical treatment, including transurethral resection, for bladder outlet obstruction (BOO) within the past 6 months prior to Visit 1
* Symptoms of severe over-active bladder (OAB):

  * Defined as an over-active bladder symptom score (OABSS) ≥12 at Visit 1
  * Defined as a mean of \>8 voids and a mean of ≥1 urgency episode per 24 hours at the end of the screening period prior to Visit 2
* Genito-urinary tract pathology that can in the investigator's opinion be responsible for urgency or urinary incontinence at Visit 1
* Complication of cancer or a history of cancer which has not been in remission for the last 5 years at Visit 1
* Current or a history of urologic malignancies, any lower urinary tract surgery, previous pelvic irradiation, or neoplasia at Visit 1
* History of any neurological disease affecting bladder function or muscle strength at Visit 1
* Urinary retention or a post void residual volume \>150 mL
* Habitual or psychogenic polydipsia based on medical history at Visit 1 or 24 hour urine output of \>2.8 L based on the voiding diary at Visit 2
* Central or nephrogenic diabetes insipidus at Visit 1
* Syndrome of inappropriate antidiuretic hormone secretion at Visit 1
* Suspicion or evidence of cardiac failure at Visit 1
* Uncontrolled hypertension at Visit 1
* Uncontrolled diabetes mellitus at Visit 1
* Hyponatraemia (serum sodium level \<135 mmol/L) at Visit 1
* Renal insufficiency at Visit 1
* Hepatic and/or biliary diseases at Visit 1
* Known or suspected hypersensitivity to desmopressin ODTs or previous desmopressin treatment for nocturia at Visit 1
* Pregnancy, breastfeeding, or a plan to become pregnant during the period of the clinical trial.
* Known alcohol or substance abuse at Visit 1
* Work or lifestyle that may interfere with regular night-time sleep at Visit 1, e.g., shift workers
* Any other medical condition, laboratory abnormality, psychiatric condition, mental incapacity, or language barrier that, in the judgment of the investigator, would impair participation in the trial at Visit 1
* Use of any prohibited therapy during the trial period

Primary outcomes:
measure: Change from baseline in mean number of nocturnal voids during 12 weeks of treatment
timeFrame: Week 1, 4, 8 and 12
Secondary outcomes:
measure: Change from baseline in mean time to first awakening to void
timeFrame: Week 1, 4, 8 and 12
measure: Change from baseline in mean nocturnal urine volume
timeFrame: Week 1, 4, 8 and 12
measure: Change from baseline in mean Nocturnal Polyuria Index (NPI)
timeFrame: Week 1, 4, 8 and 12
measure: Change from baseline in Nocturia-Specific Quality-of-Life Questionnaire (N-QoL)
timeFrame: Week 8 and 12
measure: Change from baseline in Insomnia Severity Index (ISI)
timeFrame: Week 8 and 12
measure: Change from baseline in bother score
timeFrame: Week 8 and 12
measure: Frequency and severity of adverse events
timeFrame: From screening to week 12
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: Investigational site (there may be other sites in this country)
Study officials:
affiliation: Ferring Pharmaceuticals
name: Global Clinical Compliance
role: STUDY_DIRECTOR
References:
citation: Yamaguchi O, Juul KV, Falahati A, Yoshimura T, Imura F, Kitamura M. Efficacy and safety of 25 and 50 mug desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program. Low Urin Tract Symptoms. 2020 Jan;12(1):8-19. doi: 10.1111/luts.12276. Epub 2019 Aug 9.